You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Details for Patent: 9,750,726

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,750,726 protect, and when does it expire?

Patent 9,750,726 protects ANORO ELLIPTA and TRELEGY ELLIPTA and is included in two NDAs.

This patent has sixty-six patent family members in forty countries.

Summary for Patent: 9,750,726

Title:	Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Abstract:	Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
Inventor(s):	Baker; Darrell (Middlesex, GB), Bruce; Mark (Stevenage, GB), Crater; Glenn (Mississauga, CA), Noga; Brian (Durham, NC), Thomas; Marian (Ware, GB), Wire; Patrick (Durham, NC)
Assignee:	Glaxo Group Limited (Brentford, Middlesex, GB)
Application Number:	14/970,945
Patent Claim Types: see list of patent claims	Composition; Compound; Delivery; Dosage form;

Drugs Protected by US Patent 9,750,726

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y				⤷ Try a Trial
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y				⤷ Try a Trial
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 9,750,726

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0921075.8	Dec 1, 2009

International Family Members for US Patent 9,750,726

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010326798	⤷ Try a Trial
Australia	2014204459	⤷ Try a Trial
Australia	2016262698	⤷ Try a Trial
Australia	2017238392	⤷ Try a Trial
Australia	2018282427	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.